Saint Owen Lumeni, France and Tel Aviv, Israel, October 20, 2022– (work wire) – Serpa, the leading reference in specialist clinical pathology, and Taliaz, an Israeli digital health company dedicated to improving mental health disorders, today announced a partnership with Providing clinicians with an accurate AI-driven psychiatry solution that predicts treatment efficacy in depression. By finding the right treatment from the first prescription, the test helps doctors make the best treatment decision faster for their patients and could speed the recovery of the 280 million people suffering from depression globally..
Today, 5% of adults in the world suffer from depression, which is one of the most common mental health disorders, according to the World Health Organization (1). Correct prescription of antidepressant compounds has become a critical issue in patient management as lack of response or remission occurs in 20-30% of patients who present with a major depressive episode (2). In France alone, 1 in 4 people suffer from mental health disorders, and 1 in 5 people suffer from depression.
To meet this challenge, Cerba and Taliaz have teamed up to provide clinicians with a new clinical test that predicts the effectiveness of antidepressant treatments: PREDICTIX, developed by Taliaz, harnesses a biological test paired with artificial intelligence to guide the management of depressed patients by delivering the drug with the best chance of therapeutic success the first time. Designed as a clinical decision support tool, this solution takes AI-driven precision psychiatry to the next level and is expected to improve care for millions of patients globally. It should be available to patients by January 2023 throughout the Cerba HealthCare routine clinical pathology network in France and abroad.
The PREDICTIX test uses artificial intelligence to analyze multiple streams of patient data, including genetic, metabolic, demographic and clinical information. Physicians receive a personalized patient report that predicts and rates the statistical efficacy, dosage, and potential side effects of various antidepressant medications based on each patient’s drug composition and health history. Clinical research has shown a response rate of 72.2% and real-world data has shown that 90% of patients experienced clinical improvement after 8 weeks according to the Clinical Global Impressions (CGI) scale, a useful tool for clinicians and patients used in clinical practice (3).
Jerome Salette, chief scientific officer of Cerba HealthCare comments: “With the introduction of PREDICTIX, we are entering a new era of precision medicine in psychiatry: enabling clinicians to make the best treatment decision faster, reducing the burden of depression on patients and healthcare systems. Diagnosing, improving patient health management, and facilitating the right prescription at the right time for the right patient.”
Dikel Taliaz, CEO and Co-Founder of TaliazHe said, “We are pleased to sign this historic agreement with Cerba HealthCare to help advance our mental health technology. Their scientific culture and extensive network will expand the market entry of PREDICTIX towards global reach. By harnessing the power of big data and artificial intelligence into easy-to-use and time-saving medical tools, we are committed to providing safe and effective solutions to speed recovery and reduce suffering for mentally ill patients around the world.”
1 WHO, https://www.who.int/fr/news-room/fact-sheets/detail/depressionSeptember 2021
2 National Institute of Mental Health, Sequential Therapy Alternatives Study for Relief of Depression (STAR*D)
3 Sodrow, b. et al. (2022). The effect of assigned antidepressant prescription using genetic, sociodemographic, and clinical data in patients with major depressive disorders: a clinical pilot study. Pharmacology and pharmacogenomicsAnd the 122(1), 122-130. https://doi.org/10.31488/jpp.105
View source version on businesswire.com: https://www.businesswire.com/news/home/20221020005538/ar/
Tap Cerba HealthCare Connect
Director of Communications and Public Affairs
+33 (0) 6 09 10 76 10